Back to results
US 2004/0204353 A1Published application
Intermedin and its uses
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorSheau Yu Teddy Hsu
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorSheau Yu Teddy Hsu
Estimating the term…
Intermedin nucleic acid compositions and their encoded polypeptides and variants thereof are provided. Intermedin is a novel ligand for the calcitonin receptor-like receptor. In addition to its use as a therapeutic agent, intermedin sequences are utilized in screening and research methods for the determination of specific analogs, agonists, antagonists and mimetics. Intermedin is highly expressed in the intermediate lobe of the pituitary and is shown to stimulate prolactin release by anterior pituitary cells, and to release of growth hormone. Intermedin treatment leads to blood pressure reduction both in normal and hypertensive subjects, as well as the suppression of gastric emptying activity.
A composition comprising a intermedin peptide, wherein said intermedin peptide comprises at least 18 contiguous amino acids of the sequence set forth in SEQ ID NO:2.
An isolated nucleic acid molecule comprising a cDNA sequence encoding a mammalian intermedin protein that will hybridize under stringent conditions of 50° C. or higher in the presence of 0.1×SSC to the sequence set forth in SEQ ID NO:1 or encodes the peptide in SEQ ID NO:2.
An antibody that specifically recognizes an intermedin peptide.
A non-human transgenic animal model for intermedin gene function wherein said transgenic animal comprises an introduced alteration in a intermedin gene.
A method of screening for biologically active agents that modulate intermedin function, the method comprising:
Dependencies are inferred from the claim text.